Pharma Medical News about Paclitaxel

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024
Journal of Clinical Oncology, 09/04/09

Rosenthal DI et al. – Chemotherapy soon after surgery followed by concurrent chemoradiotherapy therapy was feasible; tolerance was in line with standard postoperative chemoradiotherapy; and this regimen led to excellent rates of locoregional control and disease–free survival.

<< Previous
Covidien Announces Reporting Changes

Next >>
Abbott Listed on Dow Jones Sustainability Indexes for Fifth...

A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/09 Relevance Score: 94%

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09 Relevance Score: 92%

Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09 Relevance Score: 89%

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09 Relevance Score: 88%

Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/27/09 Relevance Score: 88%